Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Advances in Lower GI Cancer: Highlights Webinar by VJOncology
Featuring presentations & expert discussions on the latest breakthroughs and clinical developments in lower GI cancers, with a focus on data and updates from recent international meetings, including ASCO 2025, ESMO GI 2025 & ASCO GI 2026.
Chair: Rocio Garcia-Carbonero | Moderators: Anwaar Saeed, Dominik Modest
Latest with immunotherapy in dMMR/MSI-H colorectal cancer
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
Dirk Arnold Asklepios Tumorzentrum, Hamburg, Germany
Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610
Sara Lonardi Veneto Institute of Oncology - IRCCS, Venice, Italy
Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610
Caio Max S. Rocha Lima Atrium Health Wake Forest Baptist, NC, United States
Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data
Heinz-Joseph Lenz University of Southern California, Los Angeles, CA, United States
Recent progress with targeted and biomarker-driven combination strategies
BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Scott Kopetz The University of Texas MD Anderson Cancer Center, TX, United States
Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Primary overall survival (OS) analysis from the randomized, open-label, phase III STELLAR-303 study
Anwaar Saeed University of Pittsburgh, PA, United States
Updates in treatment sequencing, rechallenge and personalization
Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Final results of the randomizedby GONO
Paolo Ciraci Sapienza University of Rome, Rome, Italy
Rechallenge with amivantamab, an EGFR-MET bispecific antibody, after disease progression on prior EGFR inhibitor in left-sided RAS/BRAF wild-type metastatic colorectal cancer: Updated results from OrigAMI-1
Dirk Arnold Asklepios Tumorzentrum, Hamburg, Germany
ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG)
Jeanne Tie The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
